Neprilysin as a Biomarker: Challenges and Opportunities

Neprilysin (NEP) was more or less unrecognised by the cardiovascular community until 2014 when the Prospective Comparison of ARNi With ACEi to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) study reported impressive clinical benefits resulting from the combination of an angiotensin receptor blocker (ARB) with a neprilysin inhibitor (angiotensin receptor neprilysin inhibitor [ARNi]) over angiotensin-converting enzyme (ACE) inhibition in heart failure with reduced ejection fraction (HFrEF).
Source: Radcliffe Cardiology - Category: Cardiology Source Type: research